1. Home
  2. EQ vs RGS Comparison

EQ vs RGS Comparison

Compare EQ & RGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EQ

Equillium Inc.

HOLD

Current Price

$1.27

Market Cap

57.8M

Sector

Health Care

ML Signal

HOLD

Logo Regis Corporation

RGS

Regis Corporation

N/A

Current Price

$29.15

Market Cap

70.8M

ML Signal

N/A

Company Overview

Basic Information
Metric
EQ
RGS
Founded
2017
1922
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
57.8M
70.8M
IPO Year
2018
1991

Fundamental Metrics

Financial Performance
Metric
EQ
RGS
Price
$1.27
$29.15
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$1.00
N/A
AVG Volume (30 Days)
499.8K
8.2K
Earning Date
11-13-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
20.05
EPS
N/A
45.08
Revenue
$4,392,000.00
$223,032,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$0.66
Revenue Growth
N/A
13.98
52 Week Low
$0.27
$15.00
52 Week High
$2.35
$31.50

Technical Indicators

Market Signals
Indicator
EQ
RGS
Relative Strength Index (RSI) 62.36 56.03
Support Level $0.84 $28.54
Resistance Level $1.44 $30.24
Average True Range (ATR) 0.12 0.76
MACD 0.06 0.27
Stochastic Oscillator 74.52 66.84

Price Performance

Historical Comparison
EQ
RGS

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

About RGS Regis Corporation

Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.

Share on Social Networks: